# With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-21 18:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Key People, Organizations & Locations
ADHD, Alkermes

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| kalkinemedia.com | Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment | 2026-09-21 10:57 | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxNRkdMZFVXTVdnOXdtVXEwRHBlVEhtdzEwYlo1NHEyWE1jenNsVGlRalEyaktQSTI5cHFMaHRjalZXY05iSzR5SkJaZE1QajNLRl9vWDRDb2NwUVdrSlo2NERQbUpUQmtEYm50alU0UkhtZFJBSTdMU0U1aXVkN2psaGtibUlDYWxyWDRieDFiMkw5UmNjVFJqemZkWE9OM3lmcFpTMUpESnZGVzFrS2wxaXRKTW9IWUk1QmtZOEJXTmtTLUZwQXVRTWhR?oc=5) |
| GuruFocus | ALKS Reiterates by Needham -- Price Target Maintained at $62.00 | 2026-09-21 10:57 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxPU1dIOWFsa0lrNVY1SU83TDdFRE1VQkdrcEFmb0FTU2QyTFljZ0F4OGtZcU10eFA1R21aUzNoLThOSzhSeEVpSmtqNm92aWxYWGExWmR3a1dqNkpXV1B5SkZfX3FnTTBIRlJCZUJWcTkxT3dYMXE3dEdUeGNrOHE5TlZ2aFVtbWExbXlhbFFuMGdfZFJnWDZHODZsWTNlZw?oc=5) |
| Investor's Business Daily | What This Biotech Learned From Narcolepsy And Took To ADHD | 2026-09-21 10:57 | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxQTU1aWmZTVkJwVWkzQWo2SjhkRnVMOGZYaHVUMUo0dWNGeDBoM0g2eE9tNElUNnBRUzdRRDJrN0pIOXNqT0dIWE5OcEh0SXJNbDFwcGJxcTlvTFV3OGdqRFFiVm5WN1k2QnBfMm1rdmVzWk5BUkhlLVZIMENKWkRFSnpUWTFKQQ?oc=5) |
| STAT | Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial | 2026-09-21 10:57 | [Source Link](https://news.google.com/rss/articles/CBMie0FVX3lxTE15THgzWUluRU5zMG1VNHRnNlQ2ZUI0a0d3NW45MnlHS3VFTHZsRk43SWZlN3hXTW9TMzhvTEVQQWpMUktYcXJZOWd0ekJ2N0NJeHM0YVhUZlZYTUtyTTM2MXpQczhJYzFiNkpJaDA5clNWc3dNRllkWXV2cw?oc=5) |
| fiercebiotech.com | With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’ | 2026-09-21 10:57 | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxNNVdxa21hYkdUX1hYdUZnV2ZCbUZQSWlGa3R5OFZhMjhSTF9jMVNrQWZsdDNkclczM3U1NF9sVUR3cXVyeVNhTVRKMHRldUh3Z0xfSUxZM1VIUXI2N1VMWUUxbElqVlYybUcxZXg2WHRiSm9MbndSRmgtNF9NN0ZFRFJpYTd1UXRTQU5xZHZGZ2c3T3VCUENJSG93NWFFSks3SU5UQjJwc3lfXzlnZ1ZOY0RkZw?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-21/with-pioneering-adhd-data-alkermes-eyes-orexin-agonist-as-potential-company*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*